High Serum Advanced Glycation End Products Are Associated with Decreased Insulin Secretion in Patients with Type 2 Diabetes: A Brief Report
Table 1
Participant characteristics.
T2DM
Non-DM
value
n
15
20
Sex (male/female)
9/6
12/8
Age (years)
56.1 ± 12.0
33.9 ± 9.5
<0.001
BMI (kg/m2)
27.46 ± 4.1
21.8 ± 2.9
<0.001
Waist circumference (cm)
95.7 ± 12.3
77.2 ± 9.9
<0.001
Fasting plasma glucose (mmol/L)
6.83 ± 0.75
4.80 ± 0.43
<0.001
HbA1c (%)
7.33 ± 0.83
5.33 ± 0.27
<0.001
HbA1c (mmol/mol)
(56.6)
(35.0)
Insulinogenic index (IGI)
0.83 ± 1.07
1.44 ± 1.34
0.14
IRI-AUC
861.8 ± 429.2
616.3 ± 293.7
0.07
HOMA-%B (%)
73.7 ± 37.9
124.1 ± 68.8
<0.05
HOMA-IR
3.94 ± 2.50
1.70 ± 1.13
<0.001
Insulin sensitivity index (ISI)
4.11 ± 3.16
7.31 ± 3.32
<0.001
GDR
5.44 ± 2.34
9.52 ± 2.61
<0.001
Data are mean ± standard deviation. GDR: glucose disposal rate; HOMA-%B: homeostasis model assessment of beta cell function; HOMA-IR: homeostasis model assessment for insulin resistance; IRI-AUC: immunoreactive insulin area under the curve; Non-DM: nondiabetic study participants; T2DM: study participants with type 2 diabetes mellitus.
